Medidata, the leading global provider of cloud-based technology and data analytics for clinical research, and Syapse, a market leader in precision medicine solutions, have announced a new partnership to transform oncology clinical trials for the age of precision medicine.
Medidata and Syapse will jointly develop a portfolio of solutions to make it easier for cancer patients to access potentially life-saving clinical trials, with a focus on democratizing access for patients in community health systems. The partnership will initially build products to assist trial sponsors in designing eligibility criteria, identify community health systems as trial sites, and enable oncologists and their care teams to easily identify patients for enrollment into cutting-edge clinical trials.
“With oncology becoming increasingly focused on targeted therapy and immunotherapy, it is necessary to rethink our approach to clinical trial design in order to fully realize the vision of precision medicine,” said Glen de Vries, Medidata president and co-founder. “We’re excited to partner with Syapse to bring this vision to reality. By working at the intersection of health systems and the life sciences industry, Syapse and Medidata can both increase access to innovative clinical trials and accelerate the development of novel cancer therapies.”
Medidata’s solutions power clinical trials for 18 of the world’s top 25 pharmaceutical companies, and Syapse solutions power precision medicine for nearly 300 hospitals across 25 states. The partnership aims to bring these products to pharmaceutical companies and health systems at scale over the coming years.